Demiana Faltaos Email

VP, Head Clinical Pharmacology at Olema Oncology . Olema Oncology

Current Roles

Employees:
111
Revenue:
$17.2M
About
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Our lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com.
Olema Oncology Address
780 Brannan Street
San Francisco, CA
United States
Olema Oncology Email

Past Companies

Olema OncologyVice President, Head of Clinical Pharmacology at Olema Oncology
Mirati TherapeuticsHead of Clinical Pharmacology
Amylin Pharmaceuticals - a wholly owned subsidiary of Bristol-Myers SquibbSenior Investigator Pharmacometrics

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.